Working… Menu

Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR) (ImmunoSABR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02735850
Recruitment Status : Withdrawn (Not yet submitted, unclear timelines)
First Posted : April 13, 2016
Last Update Posted : May 23, 2017
Maastricht University Medical Center
Karolinska Institutet
University of Oxford
KU Leuven
Copenhagen University Hospital at Herlev
Catholic University of the Sacred Heart
The Netherlands Cancer Institute
Information provided by (Responsible Party):
Maastricht Radiation Oncology

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : February 2021
Estimated Study Completion Date : June 2021